Jennifer Xiang

Chief Operating Officer at Scineuro Pharmaceuticals

Health Technology

Profile

Jennifer Xiang has worked in the field of Human Resources and Operations.
She is currently the Head of Human Resources and Operations at SciNeuro Pharmaceuticals.

Jennifer Xiang active positions

Companies	Position	Start
Scineuro Pharmaceuticals Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then.	Chief Operating Officer	-

All active positions of Jennifer Xiang

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jennifer Xiang's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Scineuro Pharmaceuticals Scineuro Pharmaceuticals BiotechnologyHealth Technology SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then.	Health Technology